نتایج جستجو برای: cyp2c9 and vkorc1 polymorphisms

تعداد نتایج: 16835218  

2012
Teresa Cabaleiro Manuel Román Dolores Ochoa María Talegón Rocío Prieto-Pérez Aneta Wojnicz Rosario López-Rodríguez Jesús Novalbos Francisco Abad-Santos

Angiotensin II receptor blockers (ARBs) are used to treat hypertension. Most ARBs are metabolized by CYP2C9. The aim of this study is to evaluate the possible association between sex, polymorphisms in the CYP2C8 and CYP2C9 genes, and the pharmacokinetics of losartan, valsartan, candesartan, and telmisartan. The study population comprised 246 healthy volunteers from seven single-dose clinical tr...

Journal: :Journal of pharmacological sciences 2014
Shun-Bin Luo Chuan-Bao Li Da-Peng Dai Shuang-Hu Wang Zhen-He Wang Pei-Wu Geng Jie Cai Zhe-Li Jiang Cheng-Wei Pu Ke Shang Xin-Min Yuan Ya-Po Cao Guo-Xin Hu Jian-Ping Cai

Warfarin is the most frequently prescribed anticoagulant for the long-term treatment in the clinic. Recent studies have shown that polymorphic alleles within the CYP2C9, VKORC1, and CYP4F2 genes are related to the warfarin dosage requirement. In this study, a novel non-synonymous mutation (1009C>A) in CYP2C9 was detected in a warfarin-hypersensitive patient, while the other two candidate genes ...

Journal: :Hematology. American Society of Hematology. Education Program 2008
Charles W Francis

Polymorphisms in CYP2C9, a critical cytochrome P-450 enzyme in the metabolism of warfarin, alters its clearance and affects dosing. CYP*1 has higher activity than either the *2 or *3 variants, and patients with the *2 or *3 variants require a lower dose. VKORC1 is the enzyme inhibited by warfarin, and its levels are affected by several polymorphisms that can be divided into high or low level ha...

Journal: :WMJ : official publication of the State Medical Society of Wisconsin 2015
James K Burmester Richard L Berg John R Schmelzer Joseph J Mazza Steven H Yale

BACKGROUND Despite vast literature on warfarin, optimal strategies for temporarily discontinuing and restarting warfarin have not been established. To improve warfarin discontinuation processes, we investigated known medical and genetic factors that influence stable warfarin dose to determine how well they predict the time until patients become subtherapeutic after discontinuing warfarin. MET...

2012
Young Bum Kim Moon Ju Ko Dae Gu Lee Jong Gul Do Ji Hye Hwang

Warfarin is a frequently prescribed anticoagulant in rehabilitation patients. Adverse drug reactions of warfarin were reported as bleeding and cutaneous microvascular thrombosis. Major bleeding, such as intracranial hemorrhage and psoas hematoma, in patients receiving anticoagulation therapy is a rare condition, but sometimes very serious complication that can even be fatal. Patient-specific fa...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید